TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Number of squats
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Exercise LVEF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: LV stroke volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Patient discomfort on intubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: LUS scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: number of infants with normal profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Early Onset Neonatal Sepsis (EONS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: fentanyl Cp50incision
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Parasite clearance from peripheral blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inflammatory responses to infection (interleukin-6 levels)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Clinical complete response rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dengue seropositivity rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: emergence coughing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sore throat incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall mean satisfaction on a 10‐point visual analog scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Symptoms that interfered with activity
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Disability days
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Health status scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Reduction in agitation
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Opportunity for communication
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: duration of stay in ICU
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: neurological outcome (GOS scale)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: decrease in salt intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: improvement in dietary patterns
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: increased referral to angiography tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Virological response (HIV‐1 RNA<50 copies/ml)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: COMFORT score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Morbidity of post-stroke depression
Endpoint domain: Mortality/survival
Primary endpoint: Mean PPG increment (normalized iAUC0‐4h)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: reherniation rate
Endpoint domain: Mortality/survival
Primary endpoint: back pain (visual analog scale)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oswestry scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fatigue improvement in RNP cohort
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Worsening physical function in JHD patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient satisfaction in RNP cohort
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Surgical treatment of recurrence with curative intent
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Survival benefit from intensive follow-up
Endpoint domain: Mortality/survival
Primary endpoint: Pittsburgh Sleep Quality Index (PSQI) score
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Need for further surgery
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Responder rates for seizure control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Global Quality of Life (QoL) score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Reduction in daytime systolic ABPM
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in AHI (Apnea-Hypopnea Index)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Incidence of progression of OSA (Obstructive Sleep Apnea)
Endpoint domain: Adverse events/effects
Primary endpoint: Median time to study withdrawal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bioequivalence of atorvastatin formulations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: C(max) of atorvastatin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC(0‐t) of atorvastatin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Filtration Rate Time (FRT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Creatinine Clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: SLEDAI score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient's overall assessment of disease activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physician's overall assessment of disease activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Primary spherical aberration (Z40)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: RMS values for spherical and total HOAs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: RMS value of comatic aberrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak Dyspnea Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Diagnostic accuracy to detect MCI-like hypometabolic pattern
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: onset of disability
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: treatment attendance
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Mean decrease in ADAS-Cog score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: HAQ questionnaire score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Muscle strength of knee flexors, shoulder abductors, and wrist extensors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Breastfeeding intensity at 3 months postpartum
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: risk of diarrhoea
Endpoint domain: Adverse events/effects
Primary endpoint: proportion of cycles with no follicular rupture
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Reduction of recession depth (RD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: gains in maximal strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: muscle circumference
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: increases in anabolic hormone secretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Median tumor-free survival
Endpoint domain: Mortality/survival
Primary endpoint: Sufficient material for cytologic analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sufficient cellular material (DNA) for HPV testing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence of endocervical cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percentage of patients remaining at <50 HIV RNA copies/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: blood lactate concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Disease progression over 12 months
Endpoint domain: Mortality/survival
Primary endpoint: Delay in cone adaptation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Freezing of gait improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TUG task improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: UPDRS-III improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vemurafenib plasma concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC(0‐8h)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Agreement to check swimming pool depth before entering the water
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Reduction in TEWL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Suppression of proliferating cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: RVUs per minute
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Peptic ulcers ≥ 5 mm or with pigmented spots
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: knee joint load change during walking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rate of visual recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: final uncorrected distance visual acuity (UDVA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: True adherence with budesonide TBH treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of hypesthesia
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction in total and extracellular water content
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: complete symptomatic response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in Bergs Balance Scale score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in muscle strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in level of apathy
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Agreement among physicians for life-sustaining treatments (LSTs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Knowledge of patient preferences changing physician decisions
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Admissions for NIV and IMV
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Patient perception of pain during STB and surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Akinesia score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of mild chemosis and redness
Endpoint domain: Adverse events/effects
Primary endpoint: TVR (Target Vessel Revascularization)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: mRNA levels of survivin and annexin A4/A5
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: tumour down-staging
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total effective rate for promoting cervical maturation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cervical score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in temazepam use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VMMC quality indicators improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: KOOS pain subscore improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: KOOS symptom subscore improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete cartilage coverage of the lesion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Predictive accuracy of PVI for fluid responsiveness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Predictive accuracy of SVV for fluid responsiveness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Patient's rating of disease status
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Maximum diameter discrepancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: breast cancer recurrence
Endpoint domain: Mortality/survival
Primary endpoint: ALSAQ-40
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Average pain fear and avoidance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete control during 72 hours after study drug administration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PPV of THIN hospitalization documentation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PPV of THIN-documented pneumonia admission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Timing of hospital admissions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean intragastric pH > 4
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Respiratory function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Postoperative recovery
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: neuroprotective serum concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of major vascular events
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of major coronary events
Endpoint domain: Mortality/survival
Primary endpoint: Time to maximum fall in FEV1 % predicted
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Fall in FEV1 % predicted
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Chest tightness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Development of moderate RDS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Need for mechanical ventilation or supplemental oxygen
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Mortality associated with thromboembolism
Endpoint domain: Mortality/survival
Primary endpoint: Incremental cost associated with pulmonary embolism
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Energy intake suppression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Role physical
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Perceived health status as 'very good'
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Weight gain during pregnancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: anatomic success rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean visual acuity (VA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Low-frequency component of blood pressure variability (LF(SBP))
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Hepatic venous flow rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Systemic adriamycin exposure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of diagnosed hypoxemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Rate of myocardial ischemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: survival rate at 6, 12, and 24 months
Endpoint domain: Mortality/survival
Primary endpoint: SIA (Spherical Equivalent Astigmatism)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: GnRH stimulated LH peak <2 IU/l
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Forward physical activity stage movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cure rate of tonsillitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urine osmolality
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Copeptin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: olanzapine apparent clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Activation in the amygdala
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Activation in the insula
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Activation in the inferior frontal gyrus pars triangularis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Suicide ideation
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: percent of predicted normal FVC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: 6MWT distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: urinary glycosaminoglycans
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of bowel movements per day
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Fecal weights
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Fecal nitrogen output
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Control in ≥four of five guideline levels of risk factors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: severe exacerbation avoided
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of analgesic ampoules required
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Reduction in pruritus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severe rise in blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Prevalence of alcohol abuse or dependence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean total score on the assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Confirmed hypoglycaemia
Endpoint domain: Adverse events/effects
Primary endpoint: Levels of IL-6, MCP-1, and GM-CSF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Defecating frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Stool property
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Gastrointestinal transmission time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: NPI agitation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CMAI physical non‐aggressive behaviour (PNAB)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean gradient at rest
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: mean gradient at peak of exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Pancreatic hardness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Depression scores (BDI-II cut-off ≥ 15)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Hopelessness scores (BHS cut-off ≥ 8)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Marital distress (RDAS scores)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: weight-for-age z score (WAZ)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: length-for-age z score (LAZ)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: independent walking by 12 months
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Caregiver time burden
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Pain during injection and needle insertion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes